Primary Record
Toceranib
- In stock
- 9,102 g
- Purity
- 98.3 %
- CAS
- 356068-94-5
Compound Identifiers & Properties
- CAS
- 356068-94-5
- PubChem CID
- 5329106
- SMILES
- CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)/C=C\3/C4=C(C=CC(=C4)F)NC3=O
- Canonical SMILES
- Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCN1CCCC1
Names & Synonyms
- Toceranib
- Palladia
- 356068-94-5
- toceranibum
- Palladiar
- Toceranib free base
- Toceranib [USAN]
- Toceranib (USAN)
- Toceranib [USAN:INN]
- RefChem:57436
- TOCERANIB [INN]
- TOCERANIB [MI]
- SU11248 analog 12f
- UNII-59L7Y0530C
- AC1NS62V
- PHA-291639
- MFCD16038046
- C22H25FN4O2
- CHEMBL13608
- SU 11654
- DTXSID50189076
- BDBM4818
- orb1708344
- SCHEMBL2116670
- 59L7Y0530C
- SCHEMBL29354429
- GTPL11619
- DTXCID80111567
- QCR-132
- SRSGVKWWVXWSJT-ATVHPVEESA-N
- SU-11654
- AOB87353
- ZINC3989258
- 4124AH
- PHA291639
- AKOS024457864
- AN-3597
- CID5329106
- CS-0241
- EBC-312078
- FT44529
- PHA 291639
- SU11654
- TOCERANIB (EMA EPAR VETERINARY)
- TOCERANIB [EMA EPAR VETERINARY]
- compound 12f [PMID: 12646019]
- NCGC00378902-03
- NCGC00378902-05
- AC-26968
- AS-31877
- HY-10330
- SC-87730
- ToceranibDiscontinued Pfizer Patent issues
- BCP0726000021
- AB0072276
- DB-225126
- Toceranib(SU 11654; PHA 291639)
- 4720B
- A3879
- FT-0675258
- Toceranib(SU 11654; PHA 291639)?
- (Z)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-N-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrrole-3-carboxamide
- J3.311.001D
- A11581
- D08503
- W-5604
- (Z)-5-(5-Fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide
- EN300-7399740
- A874574
- 5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide
- BRD-K62040061-001-01-0
- BRD-K62040061-011-01-9
- B0084-455463
- 5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide
- (Z)-5-((5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-N-(2-PYRROLIDIN-1-YLETHYL)-1H-PYRROLE-3-CARBOXAMIDE
- 1H-PYRROLE-3-CARBOXAMIDE, 5-((Z)-(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-N-(2-(1-PYRROLIDINYL)ETHYL)-
- 5-[(Z)-(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide
- 5-[(Z)-(5-Fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide
- 5-[(Z)-(5-fluoro-2-oxo-indolin-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide
- 5-((Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-N-(2-(PYRROLIDIN-1-YL)ETHYL)-1H-PYRROLE-3-CARBOXAMIDE
- 5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide
- 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-(Pyrrolidin-1-yl)ethyl)amide
- 5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide
- 5-[5-fluoro-2-oxo-1, 2-dihydro-indol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide
- 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3 Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide
- 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide
- 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide
- N-[2-(Pyrrolidine-1-yl)ethyl]-5-[(Z)-(2,3-dihydro-2-oxo-5-fluoro-1H-indole-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide